Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GDT Induction and Chemoradiation for Locoregional EBV+ Nasopharyngeal Carcinoma
NCT06592599Phase 2Recruiting
- Sponsor
- Stanford University
- Start
- Sep 2024
- Primary completion
- Jan 2029
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of toripalimab in nasopharyngeal carcinoma (NPC), sponsored by Stanford University. Primary endpoints: Induction chemotherapy completion rate at 3 years and Radiation completion rate at 3 years. Started Sep 2024; status: recruiting.
02
Drugs
toripalimab
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT06592599.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06592599.